The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer.

Jacob, Susannah A; Do, Viet; Wilson, Brooke E; Ng, Weng L; Barton, Michael B

Jacob, Susannah A; Do, Viet; Wilson, Brooke E; Ng, Weng L; Barton, Michael B.

Afiliação

Jacob SA; Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
Do V; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.
Wilson BE; Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
Ng WL; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.
Barton MB; Radiation Oncology, Liverpool Hospital Cancer Therapy Centre, Sydney, NSW, Australia.

Eur J Cancer Care (Engl) ; 30(1): e13352, 2021 Jan.

Article em En | MEDLINE | ID: mdl-33146449

Assuntos

Antineoplásicos; Neoplasias da Mama; Antineoplásicos/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Análise Custo-Benefício; Feminino; Humanos

Palavras-chave

breast cancer; chemotherapy; cost; survival benefit; targeted therapy; value

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antineoplásicos Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Revista: Eur J Cancer Care (Engl) Assunto da revista: ENFERMAGEM / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google